论文部分内容阅读
目的 :探讨干扰素治疗与乙型肝炎病毒前C区突变 ( 1896位点C→A点突变 )及干扰素抗体的关系。方法 :分别以PCR法及酶联免疫吸附试验法 (ELISA)检测 86例慢性HBV感染患者血清中HBV前C区突变株及干扰素抗体。结果 :CHB重度组检出率明显高于慢性携带者及CHB轻度组 ,P <0 .0 0 5 ;38例CHB接受干扰素治疗 ,突变株组和野生株组对干扰素近期应答率相似 ,但突变株组复发率为 70 .0 % ,显著高于野生株组的 2 3.1% ;干扰素抗体阳性组的近期应答率 38.5 % ,显著低于阴性组的 72 .0 %。结论 :突变株感染与肝病严重程度有关 ,HBV前C区突变和干扰素抗体可影响干扰素的抗病毒疗效。
Objective: To investigate the relationship between interferon therapy and hepatitis B virus pre-C mutation (C → A mutation at site 1896) and interferon antibody. Methods: The serum pre-HBV mutants and interferon antibodies of 86 patients with chronic HBV infection were detected by PCR and enzyme-linked immunosorbent assay (ELISA) respectively. Results: The detection rate of CHB severe group was significantly higher than that of chronic carriers and CHB mild group (P <0.05); 38 cases of CHB received interferon treatment, the response rate of interferon to mutants and wild strains was similar , But the recurrence rate in mutant group was 70.0%, which was significantly higher than that in wild-type group (21.1%). The recent response rate of IFN-α positive group was 38.5%, which was significantly lower than that of negative group (72.0%). Conclusion: Mutant infection is related to the severity of liver disease. Mutations in pre-HBV C region and interferon antibodies may affect the antiviral efficacy of interferon.